PIRS Pieris Pharmaceuticals, Inc.

4.40-0.14 (-3.08%)
Close: August 23, 2019

Quote

Previous Close
$4.40
Day Range
$4.35-$4.67
52 Week Range
$2.39-$6.04
Volume
423,661
Avg Volume
652,578
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$217.33M
Enterprise Value (EV)
$96.14M
PE Ratio
-
EV/EBITDA
-3.18
Price/Sales
-
Price/Book
5.44
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$30.26M
EPS, ttm
-$0.77
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/26/2019 (Tomorrow)
Debt to Equity
-
Debt
$6.92M
Cash
$128.11M
Net Debt
-

Performance

Beta
1.19
200 Day Moving Avg
$3.62
50 Day Moving Avg
$4.73
52 Week Change
-16.35%
YTD Change
47.60%
1 Month Change
-3.30%
3 Month Change
-0.23%
6 Month Change
45.21%
1 Year Change
-16.35%
2 Year Change
-5.28%
5 Year Change
17.45%

Share Count

Shares Outstanding
49.4M
Float
48.2M
Restricted Shares
1.2M
Restricted Shares, %
2.50%

Pieris Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Stephen S. Yoder

Website: http://www.pieris.com

Description: Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Employees: 107